FDA Approves Livsayis as First siRNA Therapy for Generalized Myasthenia Gravis
The FDA approved Livsayis (cemdisiran), described as the first and only siRNA therapy for generalized myasthenia gravis and the only treatment with subcutaneous dosing four times a year.
Story updates
11:03:48 PM UTC
SquawkNews
Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control tha